The p21 levels have the potential to be a monitoring marker for ribociclib in breast cancer.

导出 OA

翻译打印收藏纠错

第一作者： Masafumi,Iida

第一单位： Department of Molecular and Functional Dynamics, Graduate School of Medicine, Tohoku University, Sendai, Japan.

作者： Masafumi,Iida ^[1] ; Misato,Nakamura ^[2] ; Emi,Tokuda ^[1] ; Daichi,Toyosawa ^[1] ; Toshifumi,Niwa ^[1] ; Noriaki,Ohuchi ^[1] ; Takanori,Ishida ^[2] ; Shin-Ichi,Hayashi ^[2]

作者单位： Department of Molecular and Functional Dynamics, Graduate School of Medicine, Tohoku University, Sendai, Japan. ^[1] Department of Breast and Endocrine Surgical Oncology, Graduate School of Medicine, Tohoku University, Sendai, Japan. ^[2]

关键词 CDK4/6 inhibitor CDK6 breast cancer p21 resistance

DOI 10.18632/oncotarget.27127

PMID 31448056

发布时间 2020-02-25

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览8

Oncotarget

2019年10卷47期

4907-4918页

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

The p21 levels have the potential to be a monitoring marker for ribociclib in breast cancer.

Oncotarget

相似文献

Oncotarget

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

The p21 levels have the potential to be a monitoring marker for ribociclib in breast cancer.

Oncotarget

相似文献

Oncotarget

相关期刊

检索历史清除